Clinical Antidiabetic Medication Used in Alzheimer's Disease: From Basic Discovery to Therapeutics Development

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2023 Feb 27

PMID 36845652

Authors

Juan Huang

Nanqu Huang

Di Cui

Jingshan Shi

Yu Qiu

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.

Citing Articles

The role of AMPKα subunit in Alzheimer's disease: In-depth analysis and future prospects.

Xia L, Chen J, Huang J, Lin X, Jiang J, Liu T Heliyon. 2024; 10(13):e34254.

PMID: 39071620 PMC: 11279802. DOI: 10.1016/j.heliyon.2024.e34254.

Novel targets and therapies of metformin in dementia: old drug, new insights.

Cui W, Lv C, Geng P, Fu M, Zhou W, Xiong M Front Pharmacol. 2024; 15:1415740.

PMID: 38881878 PMC: 11176471. DOI: 10.3389/fphar.2024.1415740.

Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review.

Koshatwar M, Acharya S, Prasad R, Lohakare T, Wanjari M, Taksande A Cureus. 2023; 15(9):e44763.

PMID: 37809189 PMC: 10556988. DOI: 10.7759/cureus.44763.

References

Yen Y, Kammeyer A, Tirlangi J, Ghosh A, Mesecar A . A Structure-Based Discovery Platform for BACE2 and the Development of Selective BACE Inhibitors. ACS Chem Neurosci. 2021; 12(4):581-588. PMC: 9535992. DOI: 10.1021/acschemneuro.0c00629. View

Katsenos A, Davri A, Simos Y, Nikas I, Bekiari C, Paschou S . New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs. Expert Opin Investig Drugs. 2021; 31(1):105-123. DOI: 10.1080/13543784.2022.2022122. View

Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M . Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care. 2022; 45(5):1247-1251. PMC: 9174954. DOI: 10.2337/dc21-2434. View

Kosaraju J, Murthy V, Khatwal R, Dubala A, Chinni S, Muthureddy Nataraj S . Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J Pharm Pharmacol. 2013; 65(12):1773-84. DOI: 10.1111/jphp.12148. View

Markowicz-Piasecka M, Sikora J, Szydlowska A, Skupien A, Mikiciuk-Olasik E, Huttunen K . Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla. Pharm Res. 2017; 34(12):2614-2627. PMC: 5736777. DOI: 10.1007/s11095-017-2199-y. View

Hierro-Bujalance C, Infante-Garcia C, Del Marco A, Herrera M, Carranza-Naval M, Suarez J . Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes. Alzheimers Res Ther. 2020; 12(1):40. PMC: 7140573. DOI: 10.1186/s13195-020-00607-4. View

Pantea Stoian A, Sachinidis A, Stoica R, Nikolic D, Patti A, Rizvi A . The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020; 109:154295. DOI: 10.1016/j.metabol.2020.154295. View

Sun Y, Ma C, Sun H, Wang H, Peng W, Zhou Z . Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease. J Diabetes Res. 2020; 2020:4981814. PMC: 7011481. DOI: 10.1155/2020/4981814. View

The Lancet . Lecanemab for Alzheimer's disease: tempering hype and hope. Lancet. 2022; 400(10367):1899. DOI: 10.1016/S0140-6736(22)02480-1. View

10.

Toba J, Nikkuni M, Ishizeki M, Yoshii A, Watamura N, Inoue T . PPARγ agonist pioglitazone improves cerebellar dysfunction at pre-Aβ deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice. Biochem Biophys Res Commun. 2016; 473(4):1039-1044. DOI: 10.1016/j.bbrc.2016.04.012. View

11.

Li M, Li Y, Liu Y, Huang H, Leng X, Chen Y . Altered Hippocampal Subfields Volumes Is Associated With Memory Function in Type 2 Diabetes Mellitus. Front Neurol. 2021; 12:756500. PMC: 8657943. DOI: 10.3389/fneur.2021.756500. View

12.

Low S, Goh K, Ng T, Moh A, Ang S, Wang J . Association Between Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Cognitive Function in a Longitudinal Study of Patients with Type 2 Diabetes. J Alzheimers Dis. 2022; 87(2):635-642. DOI: 10.3233/JAD-215678. View

13.

Jantrapirom S, Nimlamool W, Chattipakorn N, Chattipakorn S, Temviriyanukul P, Inthachat W . Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity. Int J Mol Sci. 2020; 21(5). PMC: 7084306. DOI: 10.3390/ijms21051725. View

14.

Gharibyan A, Islam T, Pettersson N, Golchin S, Lundgren J, Johansson G . Apolipoprotein E Interferes with IAPP Aggregation and Protects Pericytes from IAPP-Induced Toxicity. Biomolecules. 2020; 10(1). PMC: 7022431. DOI: 10.3390/biom10010134. View

15.

Xie Y, Zheng J, Li S, Li H, Zhou Y, Zheng W . GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway. Biochem Pharmacol. 2021; 188:114578. DOI: 10.1016/j.bcp.2021.114578. View

16.

Liu X, Zhang N, Zhang S, Xu P . Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1. Eur J Neurosci. 2021; 54(10):7749-7769. DOI: 10.1111/ejn.15502. View

17.

Rizvi S, Shakil S, Biswas D, Shakil S, Shaikh S, Bagga P . Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study. CNS Neurol Disord Drug Targets. 2013; 13(3):447-51. DOI: 10.2174/18715273113126660160. View

18.

OBryant S, Zhang F, Petersen M, Johnson L, Hall J, Rissman R . A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials. J Alzheimers Dis. 2021; 81(2):557-568. PMC: 8203239. DOI: 10.3233/JAD-201610. View

19.

Duarte A, Candeias E, Alves I, Mena D, Silva D, Machado N . Liraglutide Protects Against Brain Amyloid-β Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation. Int J Mol Sci. 2020; 21(5). PMC: 7084254. DOI: 10.3390/ijms21051746. View

20.

Chiang M, Cheng Y, Chen S, Yen C, Huang R . Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction. Exp Cell Res. 2016; 347(2):322-31. DOI: 10.1016/j.yexcr.2016.08.013. View